Inactive Instrument

Highlights Roche Holding AG Xetra

Equities

RHO5

CH0012032048

Highlights

Unlock all the news: Be the first to know and act before the market!

Roche: collaboration agreement with Ascidian Therapeutics	Jun. 18	CF
Roche Teams Up With Ascidian Therapeutics for RNA Gene Editing Deal	Jun. 18	DJ
Roche partners with Ascidian Therapeutics to develop gene therapies	Jun. 18	RE
Ascidian Therapeutics Enters Collaboration with Roche for Discovery and Development of RNA Exon Editing Therapeutics Targeting Neurological Diseases	Jun. 18	CI
Roche's Blood Cancer Combo Reduces Risk of Death in Late-stage Study	Jun. 17	MT
Roche?s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma	Jun. 15	CI
Roche: collaboration agreement in colon cancer	Jun. 14	CF
AbbVie inks immune disorder drug licensing deal with China's FutureGen	Jun. 13	RE
Swiss Stocks Flash Red as US Fed Decision Takes Spotlight	Jun. 10	MT
Global markets live: ABB, Roche, Microsoft, Apple, Tesla...	Jun. 10
Roche's Lung Cancer Drug Notches EU Win After 'Unprecedented' Late-stage Study Results	Jun. 10	MT
European Commission Approves Roche's Alecensa as the First and Only Targeted Adjuvant Treatment for People with ALK-Positive Early-Stage Lung Cancer	Jun. 10	CI
Roche: efficacy of Evrysdi in spinal muscular atrophy	Jun. 07	CF
Roche's Five-year Data Confirms Efficacy, Safety of Evrysdi Drug for Spinal Muscular Atrophy in Children	Jun. 07	MT
Novartis, Roche's Genentech Among Companies Facing Italian Competition Watchdog Inquiry Over Eye Drug	Jun. 07	MT
Astra's Enhertu breast cancer trial shows 'unprecedented' results	Jun. 02	RE
Astra's Enhertu delays breast cancer in patients with low HER2 levels	Jun. 02	RE
Swiss Stocks Fall as Rate Jitters Intensify Amid Latest Inflation Data	May. 29	MT
Global markets live: BHP, Anglo American, Lenovo, Nvidia, Apple...	May. 29
Roche Holding AG Announces U.S. Food and Drug Administration Accepted the New Drug Application and Granted Priority Review to Inavolisib, an Investigational, Oral Therapy, in Combination with Palbociclib (Ibrance®) and Fulvestrant	May. 29	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

ROCHE HOLDING : In line quarterly results won’t cut it for Roche

April 24, 2024 at 11:50 am EDT

Obesity: Roche joins the battle

December 04, 2023 at 10:48 am EST